Paion AG
PA8
株式のランク
#35845
Paion AG is a specialized pharmaceutical firm engaged in the global development... Paion AG is a specialized pharmaceutical firm engaged in the global development and commercialization of medicines for hospital settings, specifically addressing needs in sedation, anesthesia, and critical care. Its primary compound, Remimazolam, is an ultra-short-acting intravenous benzodiazepine designed as a sedative/anesthetic, currently progressing through clinical trials for applications in procedural sedation, general anesthesia, and intensive care unit sedation. The company's pipeline also includes Angiotensin II, a vasoconstrictor for treating severe low blood pressure in adults experiencing septic or other forms of distributive shock, and Eravacycline, a new fluorocycline antibiotic targeting complex intra-abdominal infections in adults. Paion AG collaborates with various partners through licensing and strategic agreements, including Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Established in 2000, Paion AG operates from Aachen, Germany.
株価
$0.42701586
最終同期: 2023-11-01
時価総額
$3.21M
変化（1日）
16.99%
変化（1年）
3,114.29%
国
DE
取引 Paion AG (PA8)
カテゴリー
Healthcare
の時価総額 Paion AG(PA8)
時価総額: $3.21M
October 2026時点で、Paion AG の時価総額は $3.21M です。これは、当社のデータによると、Paion AG が世界で35845th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Paion AG の時価総額の履歴（2023 から 2026 まで）
